India’s Biocon Biologics Ltd., a subsidiary of Biocon, Ltd.., has entered into a strategic out-licensing agreement for two biosimilars with Japanese company Yoshindo Inc. The deal is the first between the two companies.
Yoshindo will exclusively commercialize Biocon Biologics’ pipeline biosimilar assets ustekinumab and denosumab in Japan. Biocon will be responsible for development and manufacture
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?